Twelve Points Wealth Management’s Gilead Sciences GILD Stock Holding History

Twelve Points Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$479K	Buy	3,793 +4	+0.1%	+$527	0.1%	139
2026 Q1	$528K	Sell	3,789 -299	-7%	-$41.9K	0.12%	127
2025 Q4	$495K	Sell	4,088 -1,351	-25%	-$164K	0.11%	134
2025 Q3	$604K	Sell	5,439 -1,060	-16%	-$120K	0.15%	129
2025 Q2	$721K	Buy	6,499 +98	+2%	+$10.4K	0.19%	114
2025 Q1	$717K	Sell	6,401 -215	-3%	-$22.2K	0.19%	111
2024 Q4	$611K	Buy	+6,616	New	+$596K	0.18%	114
2022 Q4	–	Sell	-5,939	Closed	-$366K	–	167
2022 Q3	$366K	Buy	5,939 +8	+0.1%	+$504	0.28%	115
2022 Q2	$367K	Buy	5,931 +42	+0.7%	+$2.6K	0.28%	123
2022 Q1	$350K	Sell	5,889 -981	-14%	-$62.7K	0.26%	125
2021 Q4	$499K	Buy	+6,870	New	+$473K	0.4%	83

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Twelve Points Wealth Management's GILD Position: Q2 2026 in Review

Twelve Points Wealth Management increased its Gilead Sciences (GILD) stake by 0.11% in Q2 2026, buying an estimated $527 and bringing the position to 3,793 shares worth $479K. The position accounts for 0.1% of the portfolio, ranked #139.

Twelve Points Wealth Management first reported a position in GILD in Q4 2021 and has held it in 11 quarters since. The position peaked at $721K in Q2 2025. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Twelve Points Wealth Management held 3,793 shares of Gilead Sciences worth $479K as of Q2 2026.
Twelve Points Wealth Management bought 4 Gilead Sciences shares in Q2 2026, an estimated $527.
Gilead Sciences made up 0.1% of Twelve Points Wealth Management's portfolio in Q2 2026, its #139 holding.
Twelve Points Wealth Management first reported a position in Gilead Sciences in Q4 2021 and has held it in 11 quarters since.
Twelve Points Wealth Management's Gilead Sciences position peaked at $721K in Q2 2025.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Twelve Points Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.